Research Funding - Cure HHT supports investigators conducting early-stage and pilot HHT studies, funding research that generates preliminary data to help build a foundation for larger funding applications.
Funder: Cure HHT
Due Dates: Contact the research team for funding-cycle information
Funding Amounts: Historically, $50,000 seed research grants
Summary: Supports early-stage and pilot HHT research that generates preliminary data for larger funding applications.
Key Information: Investigators at any career stage are welcome, including researchers entering HHT from related vascular biology fields.
Cure HHT supports early-stage and pilot research on hereditary hemorrhagic telangiectasia (HHT), including work that needs preliminary data before a federal funding application is viable. Its seed-funding strategy supports basic, clinical, translational, and genetic science. Funding is part of a broader research infrastructure connecting investigators with registry data, biological samples, clinical sites, patient perspectives, and recruitment support.
Priority questions include preventing vascular malformations, developing durable treatment for epistaxis, understanding why the same genetic variant produces different disease severity, and investigating families with no identified variant. Cure HHT assesses requests for scientific value, feasibility, participant burden, and whether the requested resources can answer the research question.